Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of association
Abbreviations: DCR, disease control rate; NA: not available; OS, overall survival; RECIST, response evaluation in solid tumors; TTP, time to progression.
